Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians' offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit .REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that on November 17, 2024, the Compensation Committee of Adverum's Board of Directors granted an inducement award consisting of non-qualified stock options to purchase 55,000 shares of common stock to a new employee under Adverum's 2017 Inducement Plan. The Compensation Committee of Adverum's Board of Directors approved the award as an inducement material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4).
2024年11月20日,位於加利福尼亞雷德伍德城,納斯達克股票代碼爲ADVM的adverum biotechnologies公司今天宣佈,在2024年11月17日,adverum的董事會薪酬委員會授予一名新員工非合格股票期權獎勵,以購買55,000股普通股,作爲2017年adverum誘因計劃的一部分。adverum董事會薪酬委員會根據納斯達克規則5635(c)(4)批准該獎勵,作爲對新員工就業的誘因。
The stock option has an exercise price per share equal to $6.86, Adverum's closing trading price on November 15, 2024, and will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and 1/48th of the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee's continued service relationship with Adverum through the applicable vesting dates. The award is subject to the terms and conditions of Adverum's 2017 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
該期權的每股行使價格爲6.86美元,與adverum 2024年11月15日收盤交易價格相等,將在四年內解鎖,底層股票的25%將在適用解鎖開始日期的首個週年解鎖,之後每月解鎖底層股票餘額的1/48,共36個月,前提是新員工在適用解鎖日期繼續服務於adverum。該獎勵受限於adverum 2017年誘因計劃的條款和條件,以及涵蓋授予的適用獎勵協議的條款和條件。
About Adverum Biotechnologies
關於Adverum生物技術公司
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians' offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit .
adverum biotechnologies（納斯達克：ADVM）是一家臨床階段公司，旨在將基因治療確立爲高度普遍的眼科疾病的新標準治療，期望開發出恢復視力和預防失明的功能性療法。利用其專有的玻璃體內（IVT）平台的能力，adverum正在開發耐用的單次給藥療法，旨在在醫生辦公室中提供，以消除治療這些疾病所需的頻繁眼內注射。adverum正在評估其新型基因治療候選藥物ixoberogene soroparvovec（Ixo-vec，以前稱爲ADVm-022），作爲一種一次性IVT注射，針對患有新生血管或溼性年齡相關性黃斑變性的患者。此外，通過克服與現有治療方案相關的挑戰，adverum期望能夠改變治療標準，保護視力，並在全球範圍內產生深遠的社會影響。欲了解更多信息，請訪問。
Inquiries:
諮詢：
Adverum Investor Relations
Adverum投資者關係
Email: ir@adverum.com
電子郵件:ir@adverum.com
譯文內容由第三人軟體翻譯。